A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)

被引：0
|
作者：
Zhang, X. [1 ]
Cui, J. [1 ]
Quan, M. [2 ]
Zhang, T. [3 ]
Cao, D. [4 ]
Li, Z. [5 ]
Yang, D. T. C. [6 ]
Zhu, X. [6 ]
Chen, Y. [6 ]
Liang, P. [6 ]
Yao, L. [6 ]
Wang, L. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Renji Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Dept Oncol, Shanghai East Oriental Hosp, Shanghai, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Oncol, Union Hosp Tongji Med Coll, Wuhan, Peoples R China
[4] Sichuan Univ, Abdominal Oncol, West China Hosp, Chengdu, Peoples R China
[5] Harbin Med Univ, Dept Oncol, Canc Hosp, Harbin, Peoples R China
[6] Abbisko Therapeut Co Ltd, Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1533TiP
引用
收藏
页码：S934 / S935
页数：2
相关论文
共 50 条
  • [31] Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
    Wesolowski, Robert
    Sharma, Neelesh
    Reebel, Laura
    Rodal, Mary Beth
    Peck, Alexandra
    West, Brian L.
    Marimuthu, Adhirai
    Severson, Paul
    Karlin, David A.
    Dowlati, Afshin
    Le, Mai H.
    Coussens, Lisa M.
    Rugo, Hope S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [32] A Multicenter, Open-Label Phase 1 Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Advanced Solid Tumors
    Zhang, Jun
    Chavez, Jorge
    Chan, Nancy
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E27 - E27
  • [33] A multicenter, open-label, phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of JMT-101 in patients (pts) with advanced colorectal cancer (ACC).
    Li, Jian
    Shen, Lin
    Gong, Jifang
    Peng, Zhi
    Liu, Dan
    Qi, Changsong
    Yuan, Jiajia
    Hu, Rong
    Yang, Xiugao
    Li, Tao
    Fu, Dongxue
    Yang, Ruirui
    Feng, Li
    Zhang, Peng
    Chen, Xin
    Yuan, Jing
    Liu, Yuanyuan
    Wu, Zhufeng
    Cao, Ye
    Zhong, Shulin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] A Randomized, Multicenter, Open-Label Phase 3 Study to Evaluate the Safety and Efficacy of Infliximab in Pediatric Patients With Moderate to Severe Ulcerative Colitis
    Hyarns, Jeffrey S.
    Damaraju, Lakshmi
    Blank, Marion
    Johanns, Jewel
    Guzzo, Cynthia
    Winter, Harland S.
    Kugathasan, Sabra
    Cohen, Stanley A.
    Markowitz, James
    Veereman, Gigi
    Crandall, Wallace
    Baldassano, Robert
    Griffiths, Anne M.
    GASTROENTEROLOGY, 2011, 140 (05) : S124 - S125
  • [35] A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Tegoprubart (AT-1501) in Patients Undergoing Kidney Transplant
    Tchervenkov, Jean
    Coates, Patrick T.
    Kadatz, Matthew J.
    Bornstein, Jeffrey D.
    Gill, John S.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 967 - 967
  • [36] A multicenter phase II study to evaluate efficacy and safety of gefitinib as the first-line treatment for Korean patients (pts) with advanced pulmonary adenocarcinoma harboring EGFR mutations
    Kim, D.
    Lee, S.
    Lee, J.
    Lee, M.
    Kang, J.
    Kim, S.
    Shin, S.
    Kim, H.
    Heo, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors
    Harrington, Kevin Joseph
    Rullan, Antonio
    Deighton, Louise
    Barata, Joao
    Castro, Henry
    Ahlers, Christoph Matthias
    Mcrae, John
    Bommareddy, Praveen
    Coffin, Robert S.
    Middleton, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension
    Rakugi, Hiromi
    Shimizu, Kohei
    Nishiyama, Yuya
    Sano, Yuhei
    Umeda, Yuusuke
    BLOOD PRESSURE, 2018, 27 (03) : 125 - 133
  • [39] Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma
    Suzuki, Kenshi
    Sunami, Kazutaka
    Matsumoto, Morio
    Maki, Akio
    Shimada, Fumika
    Suzuki, Kazuyuki
    Shimizu, Kazuyuki
    ACTA HAEMATOLOGICA, 2021, 144 (03) : 264 - 274
  • [40] Prospective clinical study phase IIa open-label and not randomized of efficacy and toxicity of weekly paclitaxel chemotherapy in patients with advanced esophagogastric adenocarcinoma
    Diaz, C.
    Calderillo-Ruiz, G.
    Herrers, M.
    Ramos-Ramirez, M.
    Ruiz-Garcia, F.
    Takahashi, A.
    Calderillo, V.
    Horacio, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 93 - 93
12345